US Bancorp DE Has $161,000 Stock Holdings in Simulations Plus, Inc. (NASDAQ:SLP)

US Bancorp DE increased its position in shares of Simulations Plus, Inc. (NASDAQ:SLP) by 15.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,576 shares of the technology company’s stock after acquiring an additional 889 shares during the quarter. US Bancorp DE’s holdings in Simulations Plus were worth $161,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Janus Henderson Group PLC lifted its stake in Simulations Plus by 7,753.3% in the fourth quarter. Janus Henderson Group PLC now owns 542,899 shares of the technology company’s stock valued at $15,141,000 after buying an additional 535,986 shares during the period. Conestoga Capital Advisors LLC lifted its stake in Simulations Plus by 17.2% in the first quarter. Conestoga Capital Advisors LLC now owns 2,609,388 shares of the technology company’s stock valued at $63,982,000 after buying an additional 383,126 shares during the period. JPMorgan Chase & Co. lifted its stake in Simulations Plus by 210.7% in the fourth quarter. JPMorgan Chase & Co. now owns 147,154 shares of the technology company’s stock valued at $4,104,000 after buying an additional 99,789 shares during the period. Ameriprise Financial Inc. increased its holdings in shares of Simulations Plus by 16.7% in the fourth quarter. Ameriprise Financial Inc. now owns 607,902 shares of the technology company’s stock worth $16,954,000 after acquiring an additional 86,868 shares in the last quarter. Finally, Stephens Inc. AR increased its holdings in shares of Simulations Plus by 191.1% in the first quarter. Stephens Inc. AR now owns 94,439 shares of the technology company’s stock worth $2,316,000 after acquiring an additional 61,992 shares in the last quarter. Institutional investors and hedge funds own 78.08% of the company’s stock.

Analysts Set New Price Targets

SLP has been the subject of several recent analyst reports. Craig Hallum lowered their price target on Simulations Plus from $45.00 to $36.00 and set a “buy” rating for the company in a report on Friday, June 13th. BTIG Research lowered their price target on Simulations Plus from $41.00 to $25.00 and set a “buy” rating for the company in a report on Monday, July 7th. JMP Securities restated a “market perform” rating on shares of Simulations Plus in a report on Wednesday, June 18th. William Blair restated an “outperform” rating on shares of Simulations Plus in a report on Tuesday, July 15th. Finally, Zacks Research upgraded Simulations Plus to a “hold” rating in a report on Tuesday, August 12th. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $26.50.

Simulations Plus Stock Performance

Shares of NASDAQ SLP opened at $14.24 on Friday. The stock has a 50 day moving average price of $16.22 and a 200 day moving average price of $25.49. Simulations Plus, Inc. has a 52 week low of $12.39 and a 52 week high of $37.72. The stock has a market capitalization of $286.65 million, a PE ratio of -4.52 and a beta of 0.76.

Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings results on Monday, July 14th. The technology company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.26 by $0.19. Simulations Plus had a positive return on equity of 11.62% and a negative net margin of 78.63%. The firm had revenue of $20.36 million during the quarter, compared to analysts’ expectations of $22.83 million. During the same period in the prior year, the firm posted $0.27 earnings per share. The business’s quarterly revenue was up 9.8% compared to the same quarter last year. As a group, research analysts forecast that Simulations Plus, Inc. will post 1.09 EPS for the current year.

Simulations Plus Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.